Be the first person to write a business review for ImClone Systems Incorporated

ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts. ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l.

INC Research is a contract research organization (CRO) that specializes in conducting clinical trials for drugs targeting cancer, infectious diseases, and central nervous system disorders. It also has a division devoted to pediatrics. Its services include scientific and medical consulting, study monitoring, project management, and regulatory support services. The CRO operates in more than 30 countries around the globe. Its DataSpectrum subsidiary helps researchers capture and manage clinical trial data. The company was formed in 1998 as a result of the merger between the Neuroclinical Trials Center and the Integrated Neuroscience Consortium.

Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, HIV, and inflammatory diseases. The company's lede program is its JAK kinase inhibitor program, which covers treatments for inflammatory diseases and cancers, including rheumatoid arthritis, myelofibrosis, psoriasis, multiple myeloma, and prostate cancer. Incyte has several other products in clinical trial stages, including a CCR5 antagonist designed to prevent the entry of HIV into target cells.

Inhibitex, Inc. was founded in 1994 and is based in Alpharetta, Georgia. Inhibitex, Inc., a biopharmaceutical company, develops differentiated anti-infective products to prevent and treat serious infections primarily shingles and chronic hepatitis C. Its anti- infective product candidates include FV-100, an orally available nucleoside analogue prodrug, which completed Phase I trials used for the treatment of herpes zoster or shingles; and aurexis, a humanized monoclonal antibody, which completed Phase IIa trials used for the treatment of serious S. aureus infections. The company's preclinical product candidates include HCV polymerase inhibitors, which are used for the treatment of chronic HCV infection; HIV integrase inhibitors that are used for the treatment of HIV infection; and staphylococcal vaccines, an active vaccine to prevent S. aureus infections. It has MSCRAMM based license and collaboration agreement with Wyeth Pharmaceuticals for the development of staphylococcal vaccines; and royalty-bearing license agreement with Cardiff University and Katholieke Universiteit for intellectual property of HCV nucleoside polymerase inhibitors.

Inovio Biomedical Corporation was founded in 1983 and is based in San Diego, California. Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company's SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio's proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio's clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, NIH Vaccine Research Center, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.